Business »  Topic »  US generics business to continue its growth momentum: Cadila Healthcare

US generics business to continue its growth momentum: Cadila Healthcare


The US was the largest contributor to the consolidated revenues of the company with 45 per cent share, the report said.

According to the Cadila Healthcare’s annual report for fiscal year 2019-20, the company is planning to introduce additional “topical, transdermal and injectable products” in coming years.

Pharma firm Cadila Healthcare is bullish about its growth momentum in the United States driven by new product launches and expansion in overall product offerings.

According to the Cadila Healthcare’s annual report for fiscal year 2019-20, the company is planning to introduce additional “topical, transdermal and injectable products” in coming years ...


Read the full text financialexpress